Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Keybank National Association OH

Keybank National Association OH trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 9.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,091 shares of the life sciences company’s stock after selling 1,088 shares during the period. Keybank National Association OH’s holdings in Integra LifeSciences were worth $385,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Commonwealth Equity Services LLC raised its holdings in shares of Integra LifeSciences by 3.4% during the first quarter. Commonwealth Equity Services LLC now owns 7,916 shares of the life sciences company’s stock worth $454,000 after purchasing an additional 263 shares during the period. Arizona State Retirement System increased its holdings in shares of Integra LifeSciences by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock worth $802,000 after acquiring an additional 279 shares during the period. Inspire Investing LLC increased its holdings in shares of Integra LifeSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock worth $306,000 after acquiring an additional 392 shares during the period. CWM LLC increased its holdings in shares of Integra LifeSciences by 107.0% in the 2nd quarter. CWM LLC now owns 828 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 428 shares during the period. Finally, Huntington National Bank increased its holdings in shares of Integra LifeSciences by 14.7% in the 2nd quarter. Huntington National Bank now owns 3,395 shares of the life sciences company’s stock worth $140,000 after acquiring an additional 435 shares during the period. 84.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IART has been the subject of a number of recent analyst reports. CL King initiated coverage on shares of Integra LifeSciences in a research report on Tuesday, November 14th. They issued a “buy” rating and a $50.00 target price for the company. Wells Fargo & Company upgraded shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $40.00 to $49.00 in a research report on Tuesday, December 5th. Truist Financial raised their price objective on shares of Integra LifeSciences from $44.00 to $46.00 and gave the company a “hold” rating in a research report on Friday, December 22nd. JMP Securities restated a “market outperform” rating and set a $55.00 price objective on shares of Integra LifeSciences in a research report on Thursday, December 14th. Finally, StockNews.com upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, November 13th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $46.22.

View Our Latest Research Report on IART

Integra LifeSciences Trading Up 0.4 %

Shares of Integra LifeSciences stock opened at $41.18 on Thursday. The company’s fifty day simple moving average is $42.22 and its 200-day simple moving average is $40.82. The company has a market cap of $3.22 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 1.15 and a beta of 1.18. The company has a current ratio of 2.89, a quick ratio of 1.86 and a debt-to-equity ratio of 0.90. Integra LifeSciences Holdings Co. has a 1 year low of $33.44 and a 1 year high of $59.64.

About Integra LifeSciences

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Recommended Stories

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.